Launching a new global healthcare service with Emocog Co., Ltd.’s proprietary technology

Q. Please talk about the (Company name and industry status).

Emocog is a company developing end-to-end dementia management solutions based on digital therapeutics (DTx), under the mission of providing “trusted digital healthcare solutions for a healthy and happy life.” Since its establishment in 2021, it has built a unique platform encompassing dementia prevention, early diagnosis, and treatment, and is growing as a leading company in digital healthcare innovation.

Key products include the digital therapeutic device Cogthera for individuals with mild cognitive impairment, the digital cognitive screening tool Memory Pick, and the blood-based dementia diagnostic device Spectracheck. All solutions are designed based on user accessibility, scientific reliability, and technological innovation.

Q. Please explain the features and advantages of (product name).

Emocog flagship product Cogthera is the world’s only digital therapeutic device designed with a voice-based interface, allowing even elderly users unfamiliar with digital environments to use it easily. It is structured so that over 95% of patients with mild cognitive impairment (MCI) can use it independently, significantly lowering the barrier to entry.

In addition, Memory Pick is an online platform that allows anyone to access and take a cognitive test via a simple link, while Spectracheck analyzes brain disease biomarkers in the blood to significantly improve the accuracy of early dementia diagnosis. All of Emocog products are designed based on clinical data and user experience, and by offering an integrated platform capable of end-to-end management, the company delivers differentiated competitiveness in the global market.

Q. What are the company’s plans for entering overseas markets, and what is the future business direction or vision? 

Emocog began its full-scale overseas expansion in 2022 by establishing its German branch, Cogthera GmbH. Targeting entry into Germany’s digital therapeutics reimbursement system (DiGA), the company has pursued both clinical trials and certifications, successfully obtaining CE MDR certification for Cogthera. The final steps for DiGA registration are currently underway, and upon completion, the company anticipates annual sales of over KRW 10 billion within Germany.

Looking ahead, Emocog plans to expand its reach across Europe, North America, and Asia, while also broadening its business scope beyond dementia to include various mental and neurological disorders such as tic disorders and learning disabilities. Recently, the company has accelerated the development of its digital healthcare ecosystem by strengthening its distribution network from B2C to B2B through acquisitions, including HappyMind (a learning disability solution), PL Group (a pharmaceutical distribution network), and Share & Service (digital therapeutics for respiratory and cardiac rehabilitation).

Website: https://www.emocog.com/en